Assessment of the macroeconomic impact of treatment guidelines in type II diabetes mellitus in France;Évaluation de l'impact budgétaire de l'application des recommandations de bonne pratique dans le diabète de type II en France

Revue d'Epidemiologie et de Sante Publique

Volumn 53, Issue HS1, 2005, Pages

  Marissal, J P ^a   Sailly, J C ^a   Crainich, D ^a   Lebrun, T ^a  

^a UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

Author keywords

Benefit; Complications; Cost; Diabetes mellitus; France; Guidelines

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BIGUANIDE DERIVATIVE;

BLOOD PRESSURE REGULATION; BODY MASS; COST BENEFIT ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; REVIEW; SMOKING CESSATION; ADOLESCENT; ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DRUG COMBINATION; ECONOMICS; FRANCE; HEALTH CARE QUALITY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ASPIRIN; BIGUANIDES; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; FRANCE; GUIDELINE ADHERENCE; HUMANS; MIDDLE AGED; OBESITY; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; QUALITY ASSURANCE, HEALTH CARE; SMOKING CESSATION;

EID: 25444500499     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Ricordeau P, Weill A, Vallier N, Bourrel R, Guilhot J, Fender P et al. Prévalence et coût du diabète en France mé tropolitaine: quelles évolutions entre 1998 et 2000? Rev Med Ass Maladie 2002; 33: 257-65.
2. Lean MEJ, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7: 228-33.
3. Selke B, Laurent P. Impact médico-économique d'un traitement préventif des maladies cardio-vasculaires par hypolipémiants. Journal d'Économie Médicale 2001; 19: 37-55.
4. Charles MA, Basdevant A, Eschwege E. Prevalence of obesity in adults in France: the situation in 2000 established from the OBEPI Study. Ann Endocrinol (Paris) 2002; 63(2 Pt 1): 154-8.
5. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350: 829-33.
6. Bonan H, du Mesnil du Buisson MA. Enquête sur la dialyse rénale. Paris, Inspection Générale des Affaires Sociales, 1994 (rapport n° 94.092).
7. URCAM du Pays-de-Loire. Document ronéoté, 2000.
8. Échelon Régional du Service Médical d'Êle-de-France. Étude de la prise en charge du patient diabétique de type 2 en Êle-de-France. Paris, URCAM d'Île-de-France, 2000.
9. Service Médical de l'Assurance Maladie. La prise en charge des diabétiques de type II dans la région Nord-Pas-de-Calais en 1998. Lille, URCAM Nord-Pas-de-Calais, 1999.
10. Échelon Régional du Service Médical. La prise en charge des diabétiques de type II en Picardie. Amiens, URCAM de Picardie, sans date.
11. Fromentin R, Ruault G. Le diabète de type 2: une priorité de santé publique. Situation et programme d'actions en Languedoc-Roussillon. URCAM du Languedoc-Roussillon, sans date.
12. URCAM d'Auvergne. Prévalence du diabète non insulino-traité en Auvergne. URCAM d'Auvergne, 2000.
13. URCAM de Provence-Alpes-Côte d'Azur. La prise en charge des diabétiques exclusivement traités par hypoglycémiants oraux en 1999 / 1998. URCAM de Provence-Alpes-Côte d'Azur, 2000.
14. Échelon National du Service Médical de la Caisse Nationale d'Assurance Maladie des Travailleurs Salariés. La prise en charge des diabétiques exclusivement traités par antidiabétiques oraux en 1999. Paris, CNAMTS, 2000.
15. Échelon National du Service Médical de la Caisse Nationale d'Assurance Maladie des Travailleurs Salariés. La prise en charge des diabétiques exclusivement traités par antidiabétiques oraux en 2000. Paris, CNAMTS, 2002.
16. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156-63.
17. Okudaira M, Yokoyama H, Otani T, Uchigata Y, Iwamoto Y. Slightly elevated blood pressure as well as poor metabolic control are risk factors for the progression of retinopathy in early-onset Japanese type 2 diabetes. Journal of Diabetes and its Complications 2000; 14: 281-7.
18. Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 1999; 22: 1077-83.
19. Berger K, Schulte H, Stogbauer F, Assmann G. Incidence and risk factors for stroke in an occupational cohort: the PROCAM Study. Prospective Cardiovascular Muenster Study. Stroke 1998; 29: 1562-6.
20. Bostom AG, Rosenberg IH, Silbershatz H, et al. Non-fasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999; 131: 352-5.
21. McCarron P, Greenwood R, Elwood P, et al. The incidence and aetiology of stroke in the Caephilly and Speedwell Collaborative Studies II: Risk factors for ischaemic stroke. Public Health 2001; 115: 12-20.
22. Pyorälä M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Stroke 1998; 29: 1860-6.
23. Rexrode KM, Hennekens CH, Willett WC, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277: 1539-45.
24. Tanizaki Y, Kiyohara Y, Kato I, et al. Incidence and risk factors for subtypes of cerebral infarction in a general population: The Hisayama Study. Stroke 2000; 31: 2616-22.
25. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13000 strokes in 450000 people in 45 prospective cohorts. Lancet 1995; 346: 1647-53.
26. Graille V, Ferrieres J, Evans A, et al. Associations between classical cardiovascular risk factors and coronary artery disease in two countries at contrasting risk for myocardial infarction: the PRIME study. Int J Cardiol 2000; 74: 191-8.
27. Gillum RF, Mussolino ME, Madans JH. Diabetes mellitus, coronary heart disease incidence, and death from all causes in African American and European American Women. The NHANES I epidemiologic follow-up study. J Clin Epidemiol 2000; 53: 511-8.
28. Chen YT, Vaccarino V, Williams CS, Butler J, Berkman LF, Krumholz HM. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999; 106: 605-12.
29. Abramson JL, Williams SA, Krumholz HM, Vaccarino V. Moderate alcohol consumption and risk of heart failure among older persons. JAMA 2001; 285: 1971-7.
30. Antonicelli R, Gesuita R, Bolmi L, Paciaroni E. Random fasting hyperglycemia as cardiovascular risk factor in the elderly: a 6-year longitudinal study. Clin Cardiol 2001; 24: 341-4.
31. Keil U, Liese AD, Hense HW, et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality. Results from the MONICA Augsburg cohort study 1984-1992. Eur Heart J 1998; 19: 1197-207.
32. Kim KS, Owen WL, Williams D, Adams-Campbell LL. Comparison between BMI and conicity index on preventing coronary heart disease: the Framingham heart study. Ann Epidemiol 2000; 10: 424-31.
33. Njolstad I, Amesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. Circulation 1996; 93: 450-6.
34. Houterman S, Verschuren WMM, Hofman A, Witteman JCM. Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: The Rotterdam study. J Intern Med 1999; 246: 25-33.
35. 1c, cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population. Am J Kidney Dis 2000; 36: 272-81.
36. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus. A prospective cohort study of men screened for MRFIT. JAMA 1997; 278: 2069-74.
37. Mehler PS, Jeffers BW, Estacio R, Schrier RW. Associations of hypertension and complications in non-insulin-dependent diabetes mellitus. Am J Hypertens 1997; 10: 152-61.
38. Fender P, Païta M, Salanave B, Ganay D, Allemand H. Dépenses du régime général de l'Assurance-Maladie en 1994 pour les trente affections de longue durée. Santé Publique 2000; 12: 5-19.
39. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276: 1907-15.
40. Trials of Hypertension Prevention Collaborative Research Group. Effect of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The trials of hypertension prevention, phase II. Arch Intern Med 1997; 157: 657-67.
41. Huang Z, Willett WC, Manson JE, Rosner B, Stampfer MJ, Speizer FE. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998; 128: 81-8.
42. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13000 strokes in 450000 people in 45 prospective cohorts. Lancet 1995; 346: 1647-53.
43. Halimi JM, Giraudeau B, Vol S, et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000; 58: 1285-92.
44. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12.
45. Glassman AH, Covey LS, Stetnet F, Rivelli S. Smoking cessation and the course of major depression: a follow-up study. Lancet 2001; 357: 1929-32.
46. Stapleton J. Cigarette smoking prevalence, cessation and relapse. Statistical Methods in Medical Research 1998; 7: 187-203.
47. Giraud A, Fournier V, Yeu C, Logerot H, Manac'h D, Jolly D. Effectiveness and prognostic factors of success in 12 smoking cessation clinics in the hospitals of Assistance Publique-Hôpitaux de Paris. International Journal of Quality in Health Care 1996; 8: 291-6.
48. Rothman ML, Ehreth JL, Palmers CS, Collins J, Reblando JA, Luce BR. Is school health education cost effective? An exploratory analysis of selected exemplary components. Centers for Disease Control and Prevention/Battelle Institute, 1996.
49. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
50. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
51. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-13.
52. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 713-20.
53. Bretzel RG. Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy. Am J Hypertens 1997; 10: 208S-217S.
54. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
55. Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 23-33.